---
title: "Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285385401.md"
description: "Royalty Pharma plc reported Q1 2026 results with revenue of $630.58M, net income of $294.69M, and diluted EPS of $0.67, all showing year-over-year increases. Revenue grew by 11% due to new royalty acquisitions and stronger portfolio receipts, particularly in cystic fibrosis and Voranigo. The company deployed $527.9M in royalties and milestone payments and completed management internalization to enhance oversight. Upcoming regulatory and clinical catalysts are expected to impact future cash flows."
datetime: "2026-05-06T13:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285385401.md)
  - [en](https://longbridge.com/en/news/285385401.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285385401.md)
---

# Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary

Royalty Pharma plc reported first-quarter 2026 results with revenue of $630.58M, net income of $294.69M and diluted EPS of $0.67, each higher than the prior-year quarter driven by new royalty acquisitions and stronger portfolio receipts.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$630.58M

$568.25M

11%

Net income²

$294.69M

$239.35M

23.1%

Diluted EPS³

$0.67

$0.55

21.8%

_¹ Reported as “Total income and other revenues”. ² Reported as “Net income attributable to Royalty Pharma plc”. ³ Reported as “Earnings per Class A ordinary share”._

**Business Highlights**

-   Revenue growth of 11% reflected a 10.3% increase in income from financial royalty assets, supported by new acquisitions and stronger royalties including cystic fibrosis and Voranigo.
-   Portfolio receipts rose 10.3%, aided by launches and demand for Imdelltra and Amvuttra and continued growth in Trelegy, Evrysdi and Tremfya.
-   Deployed $527.9M in Q1 2026 on royalties and milestone payments, including investments in Avlayah, Ziihera and new R&D funding agreements.
-   Completed internalization of management on May 16, 2025, increasing in‑house oversight and driving higher share‑based compensation recognition.
-   Multiple regulatory and clinical catalysts—approvals and positive trial readouts such as Alyftrek, Spinraza high dose and Avlayah—are expected to influence future cash flows.

Original SEC Filing: Royalty Pharma plc \[ RPRX \] - 10-Q - May. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)
- [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)